Osage University Partners was among the investors in the University of California San Diego spinout's latest round, which will support phase 1 trial for its lead compound.
US-based human papilloma virus (HPV) treatment developer Antiva Biosciences raised $22m in a series C round yesterday featuring spinout-focused venture capital firm Osage University Partners.
Brace Pharma Capital, the strategic investment arm of pharmaceutical company EMS, led the round, which included Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria Real Estate Equities, as well as NS Investment, Canaan Partners and Sofinnova Ventures.
Founded in 2012 as Hera Therapeutics, Antiva is working on topical treatments for pre-cancerous…